全文获取类型
收费全文 | 3133篇 |
免费 | 305篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 115篇 |
妇产科学 | 65篇 |
基础医学 | 334篇 |
口腔科学 | 42篇 |
临床医学 | 245篇 |
内科学 | 691篇 |
皮肤病学 | 248篇 |
神经病学 | 164篇 |
特种医学 | 152篇 |
外科学 | 508篇 |
综合类 | 201篇 |
一般理论 | 6篇 |
预防医学 | 174篇 |
眼科学 | 76篇 |
药学 | 134篇 |
中国医学 | 13篇 |
肿瘤学 | 219篇 |
出版年
2023年 | 43篇 |
2022年 | 19篇 |
2021年 | 97篇 |
2020年 | 80篇 |
2019年 | 90篇 |
2018年 | 97篇 |
2017年 | 74篇 |
2016年 | 92篇 |
2015年 | 94篇 |
2014年 | 107篇 |
2013年 | 125篇 |
2012年 | 174篇 |
2011年 | 212篇 |
2010年 | 87篇 |
2009年 | 100篇 |
2008年 | 138篇 |
2007年 | 165篇 |
2006年 | 177篇 |
2005年 | 142篇 |
2004年 | 135篇 |
2003年 | 132篇 |
2002年 | 125篇 |
2001年 | 94篇 |
2000年 | 104篇 |
1999年 | 95篇 |
1998年 | 31篇 |
1997年 | 29篇 |
1996年 | 29篇 |
1995年 | 28篇 |
1994年 | 41篇 |
1993年 | 39篇 |
1992年 | 55篇 |
1991年 | 46篇 |
1990年 | 37篇 |
1989年 | 43篇 |
1988年 | 37篇 |
1987年 | 51篇 |
1986年 | 41篇 |
1985年 | 34篇 |
1984年 | 24篇 |
1983年 | 13篇 |
1982年 | 10篇 |
1980年 | 5篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1976年 | 4篇 |
1974年 | 7篇 |
1973年 | 8篇 |
1968年 | 4篇 |
1967年 | 6篇 |
排序方式: 共有3463条查询结果,搜索用时 15 毫秒
1.
Hui Xing Lau Sarah El-Heis Qai Ven Yap Yiong Huak Chan Cheryl Pei Ting Tan Neerja Karnani Karen Mei Ling Tan Elizabeth Huiwen Tham Anne Eng Neo Goh Oon Hoe Teoh Kok Hian Tan Johan Gunnar Eriksson Yap Seng Chong Mary Foong-Fong Chong Hugo Van Bever Bee Wah Lee Lynette P. Shek Keith M. Godfrey Evelyn Xiu Ling Loo 《Clinical and experimental allergy》2021,51(10):1346-1360
2.
3.
4.
5.
6.
Lu Ping Tan Geok Wee Tan Vijaya Mohan Sivanesan Siang Ling Goh Xun Jin Ng Chun Shen Lim Wee Ric Kim Taznim Begam Binti Mohd Mohidin Nor Soleha Mohd Dali Siew Hoon Ong Chun Ying Wong Halimuddin Sawali Yoke Yeow Yap Faridah Hassan Kin Choo Pua Cheng Eng Koay Ching Ching Ng Alan Soo-Beng Khoo the Malaysian Nasopharyngeal Carcinoma Study Group 《International journal of cancer. Journal international du cancer》2020,146(8):2336-2347
Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling. 相似文献
7.
8.
INTRODUCTIONRecent studies reported that laparoscopic pancreatoduodenectomy (LPD) is associated with superior perioperative outcomes compared to the open approach. However, concerns have been raised about the safety of LPD, especially during the learning phase. Robotic pancreatoduodenectomy (RPD) has been reported to be associated with a shorter learning curve compared to LPD. We herein present our initial experience with RPD.METHODSA retrospective review of a single-institution prospective robotic hepatopancreaticobiliary (HPB) surgery database of 70 patients identified seven consecutive RPDs performed by a single surgeon in 2016–2017. These were matched at a 1:2 ratio with 14 open pancreatoduodenectomies (OPDs) selected from 77 consecutive pancreatoduodenectomies performed by the same surgeon between 2011 and 2017.RESULTSSeven patients underwent RPD, of which five were hybrid procedures with open reconstruction. There were no open conversions. Median operative time was 710.0 (range 560.0–930.0) minutes. Two major morbidities (> Grade 2) occurred: one gastrojejunostomy bleed requiring endoscopic haemostasis and one delayed gastric emptying requiring feeding tube placement. There were no pancreatic fistulas, reoperations or 90-day/in-hospital mortalities in the RPD group. Comparison between RPD and OPD demonstrated that RPD was associated with a significantly longer operative time. Compared to open surgery, there was no significant difference in estimated blood loss, blood transfusion, postoperative stay, pancreatic fistula rates, morbidity and mortality rates, R0 resection rates, and lymph node harvest rates.CONCLUSIONOur initial experience demonstrates that RPD is feasible and safe in selected patients. It can be safely adopted without any compromise in patient outcomes compared to the open approach. 相似文献
9.
10.